Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years
Hadigal et al. argued the recommendation of high-dose influenza vaccine over standard-dose formulation is not supported by comparisons of numbers-needed-to-vaccinate (NNV) nor aligned with the WHO mandate of improving vaccine coverage. However, the authors’ NNV calculation was inaccurate. A preferen...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Taylor & Francis Group
2022-11-01
|
| Serie: | Human Vaccines & Immunotherapeutics |
| Accesso online: | http://dx.doi.org/10.1080/21645515.2022.2106749 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|